NCT01566721 (SafeHER) is a Phase 3 clinical trial of Herceptin in Breast Neoplasms, sponsored by Hoffmann-La Roche.

Who is sponsoring NCT01566721?

NCT01566721 is sponsored by Hoffmann-La Roche.

What drugs are being tested in NCT01566721?

Interventions in NCT01566721: Herceptin.

What condition does NCT01566721 study?

NCT01566721 studies Breast Neoplasms.

Is NCT01566721 still recruiting?

NCT01566721 is currently completed. Last updated 27 April 2021.

Are results published for NCT01566721?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-04-27 · How we verify

NCT01566721: SafeHER

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

Completed Phase 3 Results posted Last updated 27 April 2021

What this trial tests

Phase 3 trial testing Herceptin in Breast Neoplasms in 2,577 participants. Completed in 19 February 2020.

Timeline

17 May 2012

Primary endpoint
10 March 2015

19 February 2020

Quick facts

Lead sponsor	Hoffmann-La Roche
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	2,577
Start date	17 May 2012
Primary completion	10 March 2015
Estimated completion	19 February 2020
Sites	437 locations across Hong Kong, Colombia, Italy, Panama, Ecuador, Malaysia, Taiwan, Ireland

Drugs / interventions tested

Herceptin (trastuzumab) — full drug profile →

Conditions studied

Breast Neoplasms — all drugs for Breast Neoplasms →

Sponsor

Hoffmann-La Roche — full company profile →

Who can join

18 and older, any sex, with Breast Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Percentage of Participants With At Least 1 Adverse Event (AE) During the Treatment Period Primary · From Day 1 up to 19 cycles (cycle length 3 weeks) (approximately 1 year)

Participants were planned to receive a total of 18 cycles of SC Herceptin. An AE was defined as any untoward medical occurrence in a participant administered SC Herceptin. Examples included unfavorable/unintended signs and symptoms, new or exacerbated disease, recurrence of intermittent condition, deterioration in laboratory value or other clinical test, or adverse procedure-related events. The percentage of participants with at least 1 AE during the treatment period (regardless of severity or seriousness) was reported.

Group	Value	95% CI
Cohort A: SC Herceptin by Needle/Syringe	88.6
Cohort B: SC Herceptin by SID	89.0

Percentage of Participants With a Grade 3 or Higher AE During the Treatment Period Primary · From Day 1 up to 19 cycles (cycle length 3 weeks) (approximately 1 year)

Participants were planned to receive a total of 18 cycles of SC Herceptin. An AE was defined as any untoward medical occurrence in a participant administered SC Herceptin. Examples included unfavorable/unintended signs and symptoms, new or exacerbated disease, recurrence of intermittent condition, deterioration in laboratory value or other clinical test, or adverse procedure-related events. AEs were graded according to National Cancer Institute Common Terminology Criteria Version 4.0. Grade 3 AEs were those considered severe or medically significant but not immediately life-threatening. Grade

Group	Value	95% CI
Cohort A: SC Herceptin by Needle/Syringe	24.0	22.1 – 26.0
Cohort B: SC Herceptin by SID	21.0	18.1 – 24.2

Percentage of Participants With Treatment Interruption Due to an AE Primary · From Day 1 up to 19 cycles (cycle length 3 weeks) (approximately 1 year)

Participants were planned to receive a total of 18 cycles of SC Herceptin. An AE was defined as any untoward medical occurrence in a participant administered SC Herceptin. Examples included unfavorable/unintended signs and symptoms, new or exacerbated disease, recurrence of intermittent condition, deterioration in laboratory value or other clinical test, or adverse procedure-related events. The percentage of participants with SC Herceptin treatment interrupted to assess or treat AEs was reported.

Group	Value	95% CI
Cohort A: SC Herceptin by Needle/Syringe	9.8
Cohort B: SC Herceptin by SID	10.4

Number of Herceptin Cycles Received Primary · From Day 1 up to 19 cycles (cycle length 3 weeks) (approximately 1 year)

Participants were planned to receive a total of 18 cycles of SC Herceptin. The median number of cycles actually received was reported.

Group	Value	95% CI
Cohort B: SC Herceptin by SID (Self-Administered)	16.0	1 – 17
Cohort A: SC Herceptin by Needle/Syringe	18.0	1 – 19
Cohort B: SC Herceptin by SID	18.0	1 – 18

Percentage of Participants by Total Number of Herceptin Cycles Received Primary · From Day 1 up to 19 cycles (cycle length 3 weeks) (approximately 1 year)

Participants were planned to receive a total of 18 cycles of SC Herceptin. The percentage of participants was reported by the total number of cycles actually received. Because the data are presented non-cumulatively, this table reflects participant distribution by the highest number of cycles received.

1 Cycle Received

Group	Value	95% CI
Cohort B: SC Herceptin by SID (Self- Administered)	2.7
Cohort A: SC Herceptin by Needle/Syringe	1.0
Cohort B: SC Herceptin by SID	0.8

2 Cycles Received

Group	Value	95% CI
Cohort B: SC Herceptin by SID (Self- Administered)	1.3
Cohort A: SC Herceptin by Needle/Syringe	0.5
Cohort B: SC Herceptin by SID	0.4

3 Cycles Received

Group	Value	95% CI
Cohort B: SC Herceptin by SID (Self- Administered)	1.1
Cohort A: SC Herceptin by Needle/Syringe	0.5
Cohort B: SC Herceptin by SID	0.1

4 Cycles Received

Group	Value	95% CI
Cohort B: SC Herceptin by SID (Self- Administered)	1.6
Cohort A: SC Herceptin by Needle/Syringe	1.2
Cohort B: SC Herceptin by SID	0.7

5 Cycles Received

Group	Value	95% CI
Cohort B: SC Herceptin by SID (Self- Administered)	1.3
Cohort A: SC Herceptin by Needle/Syringe	0.8
Cohort B: SC Herceptin by SID	0.6

6 Cycles Received

Group	Value	95% CI
Cohort B: SC Herceptin by SID (Self- Administered)	1.6
Cohort A: SC Herceptin by Needle/Syringe	0.5
Cohort B: SC Herceptin by SID	0.1

7 Cycles Received

Group	Value	95% CI
Cohort B: SC Herceptin by SID (Self- Administered)	2.2
Cohort A: SC Herceptin by Needle/Syringe	0.7
Cohort B: SC Herceptin by SID	0.8

8 Cycles Received

Group	Value	95% CI
Cohort B: SC Herceptin by SID (Self- Administered)	2.2
Cohort A: SC Herceptin by Needle/Syringe	0.9
Cohort B: SC Herceptin by SID	0.3

Percentage of Participants Who Received Concomitant Cancer Therapy Primary · From Baseline to data cutoff of 10 March 2015 (up to approximately 3 years)

Concomitant cancer treatment included chemotherapy, radiotherapy, and hormone therapy administered during the study. The percentage of participants who received any of these concomitant therapies was reported.

Chemotherapy

Group	Value	95% CI
Cohort A: SC Herceptin by Needle/Syringe	58.2
Cohort B: SC Herceptin by SID	63.9

Radiotherapy

Group	Value	95% CI
Cohort A: SC Herceptin by Needle/Syringe	51.3
Cohort B: SC Herceptin by SID	48.5

Hormone Therapy

Group	Value	95% CI
Cohort A: SC Herceptin by Needle/Syringe	53.5
Cohort B: SC Herceptin by SID	50.4

Percentage of Participants Who Received Concomitant Non-Cancer Therapy Primary · From Baseline to data cutoff of 10 March 2015 (up to approximately 3 years)

Concomitant non-cancer treatment included any pharmacologic interventions administered during the study other than chemotherapy, radiotherapy, or hormone therapy. The percentage of participants who received any concomitant non-cancer therapies was reported.

Group	Value	95% CI
Cohort A: SC Herceptin by Needle/Syringe	89.1
Cohort B: SC Herceptin by SID	89.7

Percentage of Participants Who Died by Data Cutoff of 10 March 2015 Secondary · From Baseline to time of event (maximum follow-up approximately 3 years as of data cutoff of 10 March 2015)

The percentage of participants who died from any cause was reported.

Group	Value	95% CI
Cohort A: SC Herceptin by Needle/Syringe	1.5
Cohort B: SC Herceptin by SID	0.8

Percentage of Participants Who Died During the Safety Follow-up Period Secondary · From Baseline to Time of Event, Safety Follow-Up Period (Up to 6 Years)

The percentage of participants who died from any cause was reported during the safety follow-up period.

Group	Value	95% CI
Cohort A: SC Herceptin by Needle/Syringe	6.8
Cohort B: SC Herceptin by SID	7.3

Disease-Free Survival Rate Secondary · From Baseline to time of event (up to approximately 8 years)

DFS is defined as the time from first dose of SC Herceptin to the first event of local, regional or distant recurrence, contralateral invasive breast cancer (including ipsilateral ductal carcinoma in situ) or death due to any cause. Time from the date of first dose to any DFS event was expressed in Kaplan-Meier survival probability estimates. Patients without an event will be censored at the last assessment date.

0.5 Year

Group	Value	95% CI
Cohort A: SC Herceptin by Needle/Syringe	0.990	0.984 – 0.993
Cohort B: SC Herceptin by SID	0.987	0.976 – 0.993

1 Year

Group	Value	95% CI
Cohort A: SC Herceptin by Needle/Syringe	0.975	0.967 – 0.981
Cohort B: SC Herceptin by SID	0.976	0.961 – 0.985

1.5 Year

Group	Value	95% CI
Cohort A: SC Herceptin by Needle/Syringe	0.960	0.950 – 0.968
Cohort B: SC Herceptin by SID	0.957	0.939 – 0.970

2 Years

Group	Value	95% CI
Cohort A: SC Herceptin by Needle/Syringe	0.934	0.921 – 0.944
Cohort B: SC Herceptin by SID	0.939	0.918 – 0.955

3 Years

Group	Value	95% CI
Cohort A: SC Herceptin by Needle/Syringe	0.904	0.889 – 0.917
Cohort B: SC Herceptin by SID	0.896	0.870 – 0.916

4 Years

Group	Value	95% CI
Cohort A: SC Herceptin by Needle/Syringe	0.881	0.865 – 0.896
Cohort B: SC Herceptin by SID	0.874	0.847 – 0.897

5 Years

Group	Value	95% CI
Cohort A: SC Herceptin by Needle/Syringe	0.868	0.851 – 0.883
Cohort B: SC Herceptin by SID	0.863	0.835 – 0.887

6 Years

Group	Value	95% CI
Cohort A: SC Herceptin by Needle/Syringe	0.851	0.833 – 0.867
Cohort B: SC Herceptin by SID	0.853	0.824 – 0.878

Overall Survival Rate Secondary · From Baseline to Time of Event (Up to Approximately 6 Years)

Overall survival was defined as the time from randomization to death from any cause. Time from the date of randomization to the date of death was expressed in Kaplan-Meier survival probability estimates. Patients without an event will be censored at the last assessment date.

0.5 Year

Group	Value	95% CI
Cohort A: SC Herceptin by Needle/Syringe	0.999	0.996 – 1.000
Cohort B: SC Herceptin by SIDE	0.996	0.987 – 0.999

1 Year

Group	Value	95% CI
Cohort A: SC Herceptin by Needle/Syringe	0.998	0.994 – 0.999
Cohort B: SC Herceptin by SIDE	0.994	0.985 – 0.998

1.5 Year

Group	Value	95% CI
Cohort A: SC Herceptin by Needle/Syringe	0.993	0.988 – 0.996
Cohort B: SC Herceptin by SIDE	0.990	0.979 – 0.995

2 Years

Group	Value	95% CI
Cohort A: SC Herceptin by Needle/Syringe	0.985	0.979 – 0.990
Cohort B: SC Herceptin by SIDE	0.985	0.973 – 0.992

3 Years

Group	Value	95% CI
Cohort A: SC Herceptin by Needle/Syringe	0.968	0.958 – 0.975
Cohort B: SC Herceptin by SIDE	0.960	0.942 – 0.972

4 Years

Group	Value	95% CI
Cohort A: SC Herceptin by Needle/Syringe	0.947	0.935 – 0.956
Cohort B: SC Herceptin by SIDE	0.950	0.931 – 0.965

5 Years

Group	Value	95% CI
Cohort A: SC Herceptin by Needle/Syringe	0.937	0.925 – 0.948
Cohort B: SC Herceptin by SIDE	0.929	0.907 – 0.947

6 Years

Group	Value	95% CI
Cohort A: SC Herceptin by Needle/Syringe	0.927	0.913 – 0.938
Cohort B: SC Herceptin by SIDE	0.921	0.897 – 0.939

Percentage of Participants by Item Response to SID Satisfaction Questionnaire Secondary · Cycle 4 (cycle length 3 weeks) and last safety follow-up (LSFU) (approximately 1 year)

The SID satisfaction questionnaire was administered twice during the study and asked participants to respond to five statements using a Likert scale from "Strongly Disagree" to "Strongly Agree". Questionnaire items were as follows: "I felt comfortable injecting the study drug by myself" (Comfortable), "The SID was convenient and easy to use" (Easy to Use), "I am confident giving myself an injection in the thigh with the SID" (Confident), "Taking all things into account I find self-administration using the SID satisfactory" (Satisfactory), "If given the opportunity I would choose to continue se

Cycle 4: Comfortable, Strongly Disagree (n=514)

Group	Value	95% CI
Cohort B: SC Herceptin by SID (Self- Administered)	4.7

Cycle 4: Comfortable, Disagree (n=514)

Group	Value	95% CI
Cohort B: SC Herceptin by SID (Self- Administered)	2.3

Cycle 4: Comfortable, Unsure (n=514)

Group	Value	95% CI
Cohort B: SC Herceptin by SID (Self- Administered)	7.6

Cycle 4: Comfortable, Agree (n=514)

Group	Value	95% CI
Cohort B: SC Herceptin by SID (Self- Administered)	41.6

Cycle 4: Comfortable, Strongly Agree (n=514)

Group	Value	95% CI
Cohort B: SC Herceptin by SID (Self- Administered)	43.6

Cycle 4: Comfortable, Response Missing (n=514)

Group	Value	95% CI
Cohort B: SC Herceptin by SID (Self- Administered)	0.2

Cycle 4: Easy to Use, Strongly Disagree (n=514)

Group	Value	95% CI
Cohort B: SC Herceptin by SID (Self- Administered)	3.7

Cycle 4: Easy to Use, Disagree (n=514)

Group	Value	95% CI
Cohort B: SC Herceptin by SID (Self- Administered)	0.6

Adverse events — posted to ClinicalTrials.gov

Time frame: Treatment Period: From Day 1 up to 19 cycles (approximately 1 year) 15 March 2015 Data Cutoff Safety Follow-up Period (SFU): From Day 1 to safety follow-up period (up to approximately 8 years). Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Cohort A: SC Herceptin by Needle/Syringe

Serious: 242/1864 (13%)

Deaths: —

Cohort B: SC Herceptin by SID

Serious: 84/709 (12%)

Deaths: —

Cohort A: SC Herceptin by Needle/Syringe Safety Follow-up

Serious: 202/1862 (11%)

Deaths: —

Cohort B: SC Herceptin by SID Safety Follow-up

Serious: 53/707 (7%)

Deaths: —

Serious adverse events (345 terms)

Reaction	System	Cohort A: SC Herceptin by …	Cohort B: SC Herceptin by …	Cohort A: SC Herceptin by …	Cohort B: SC Herceptin by …
Febrile neutropenia	Blood and lymphatic system disorders	—	—	—	—
Breast cancer	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—	—	—
Pyrexia	General disorders	—	—	—	—
Cardiac failure congestive	Cardiac disorders	—	—	—	—
Neutropenic sepsis	Infections and infestations	—	—	—	—
Neutropenia	Blood and lymphatic system disorders	—	—	—	—
Pneumonia	Infections and infestations	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—
Device related infection	Infections and infestations	—	—	—	—
Death	General disorders	—	—	—	—
Atrial fibrillation	Cardiac disorders	—	—	—	—
Myocardial Infarction	Cardiac disorders	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—
Mastitis	Infections and infestations	—	—	—	—
Cellulitis	Infections and infestations	—	—	—	—
Lower respiratory tract infection	Infections and infestations	—	—	—	—
Pulmonary embolism	Respiratory, thoracic and mediastinal disorders	—	—	—	—
Urinary tract infection	Infections and infestations	—	—	—	—
Gastroenteritis	Infections and infestations	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—
Pancreatitis	Gastrointestinal disorders	—	—	—	—
Acute myocardial infarction	Cardiac disorders	—	—	—	—
Ejection fraction decreased	Investigations	—	—	—	—
Uterine polyp	Reproductive system and breast disorders	—	—	—	—
Cholelithiasis	Hepatobiliary disorders	—	—	—	—

Other adverse events (44 terms — click to expand)

Reaction	System	Cohort A: SC Herceptin by …	Cohort B: SC Herceptin by …	Cohort A: SC Herceptin by …	Cohort B: SC Herceptin by …
Fatigue	General disorders	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—
Arthralgia	Musculoskeletal and connective tissue disorders	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—
Myalgia	Musculoskeletal and connective tissue disorders	—	—	—	—
Headache	Nervous system disorders	—	—	—	—
Asthenia	General disorders	—	—	—	—
Pain in extremity	Musculoskeletal and connective tissue disorders	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—
Pyrexia	General disorders	—	—	—	—
Rash	Skin and subcutaneous tissue disorders	—	—	—	—
Hot flush	Vascular disorders	—	—	—	—
Alopecia	Skin and subcutaneous tissue disorders	—	—	—	—
Radiation skin injury	Injury, poisoning and procedural complications	—	—	—	—
Oedema peripheral	General disorders	—	—	—	—
Erythema	Skin and subcutaneous tissue disorders	—	—	—	—
Constipation	Gastrointestinal disorders	—	—	—	—
Nasopharyngitis	Infections and infestations	—	—	—	—
Hypertension	Vascular disorders	—	—	—	—
Neuropathy peripheral	Nervous system disorders	—	—	—	—
Anaemia	Blood and lymphatic system disorders	—	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—	—
Injection site erythema	General disorders	—	—	—	—
Injection site pain	General disorders	—	—	—	—
Stomatitis	Gastrointestinal disorders	—	—	—	—
Pruritus	Skin and subcutaneous tissue disorders	—	—	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—	—
Upper respiratory tract infection	Infections and infestations	—	—	—	—
Paraesthesia	Nervous system disorders	—	—	—	—
Dizziness	Nervous system disorders	—	—	—	—
Epistaxis	Respiratory, thoracic and mediastinal disorders	—	—	—	—
Insomnia	Psychiatric disorders	—	—	—	—
Mucosal inflammation	General disorders	—	—	—	—
Injection site reaction	General disorders	—	—	—	—
Neutropenia	Blood and lymphatic system disorders	—	—	—	—
Peripheral sensory neuropathy	Nervous system disorders	—	—	—	—
Urinary tract infection	Infections and infestations	—	—	—	—
Musculoskeletal pain	Musculoskeletal and connective tissue disorders	—	—	—	—
Abdominal pain	Gastrointestinal disorders	—	—	—	—

Most-reported serious reactions: Febrile neutropenia, Breast cancer, Pyrexia, Cardiac failure congestive, Neutropenic sepsis, Neutropenia, Pneumonia, Diarrhoea.

Data from ClinicalTrials.gov NCT01566721 adverse events section.

Sponsor's own description

This multicenter, two-cohort, non-randomized, open-label study will evaluate the safety and tolerability of assisted and self-administered SC Herceptin as adjuvant therapy in participants with early HER2-positive breast cancer following tumor excision. Participants will receive Herceptin 600 milligrams (mg) SC every 3 weeks for 18 cycles, either by an assisted administration using a conventional syringe and needle/vial formulation (Cohort A) or with assisted and self-administration using a single-use injection device (SID) in selected participants (Cohort B).

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase.
Shpilberg O, Jackisch C. · · 2013 · cited 88× · PMID 24002601 · DOI 10.1038/bjc.2013.371
Subcutaneous Administration of Monoclonal Antibodies in Oncology.
Jackisch C, Müller V, Maintz C, Hell S, et al · · 2014 · cited 65× · PMID 25076790 · DOI 10.1055/s-0034-1368173
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.
Gligorov J, Ataseven B, Verrill M, De Laurentiis M, et al · · 2017 · cited 36× · PMID 28625777 · DOI 10.1016/j.ejca.2017.05.010
Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study.
North RT, Harvey VJ, Cox LC, Ryan SN. · · 2015 · cited 36× · PMID 26251623 · DOI 10.2147/ceor.s85599
Subcutaneous Trastuzumab for HER2-positive Breast Cancer - Evidence and Practical Experience in 7 German Centers.
Jackisch C, Müller V, Dall P, Neumeister R, et al · · 2015 · cited 35× · PMID 26166837 · DOI 10.1055/s-0035-1546172
Evolving landscape of human epidermal growth factor receptor 2-positive breast cancer treatment and the future of biosimilars.
Jackisch C, Lammers P, Jacobs I. · · 2017 · cited 32× · PMID 28236776 · DOI 10.1016/j.breast.2017.01.010
A multidisciplinary perspective on the subcutaneous administration of trastuzumab in HER2-positive breast cancer.
Dent S, Ammendolea C, Christofides A, Edwards S, et al · · 2019 · cited 26× · PMID 30853812 · DOI 10.3747/co.26.4220
Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer.
Hamizi S, Freyer G, Bakrin N, Henin E, et al · · 2013 · cited 16× · PMID 23430730 · DOI 10.2147/ott.s27733

Verify or expand the search:

Other trials of Herceptin

Trials testing the same drug.

NCT03879577 — Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer · Phase 2 · active not recruiting
NCT04905667 — Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin ® · Phase 1 · completed
NCT03989037 — A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast Cancer · Phase 3 · completed
NCT05301530 — Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Brea · Phase 1 · completed
NCT03433313 — Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer · Phase 3 · completed

Other recruiting trials for Breast Neoplasms

Currently open trials in the same condition.

NCT07214532 — Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer · NA · recruiting
NCT07500428 — Construction of a Benchmark for Breast Ultrasound AI Interpretation and Performance Evaluation of Multimodal AI Models · recruiting
NCT07581834 — Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multic · Phase 2 · recruiting
NCT07222215 — PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) · Phase 2 · recruiting
NCT07465393 — Facility-Based Multi-Modal Rehab vs. Home-Based Resistance Exercise for Quality of Life in Breast Cancer Survivors · NA · recruiting

Other Hoffmann-La Roche trials

Trials by the same sponsor.

NCT07503340 — A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous O · Phase 2 · not yet recruiting
NCT07298421 — A Study to Assess the Pharmacokinetics, Effectiveness and Safety of Afimkibart for Induction and Maintenance Therapy in · Phase 3 · recruiting
NCT07059273 — A COPD Data Registry for Participants With Frequent Exacerbations · not yet recruiting
NCT07416526 — A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in Participants With Hemophilia A · Phase 3 · recruiting
NCT05199688 — A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01566721 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hoffmann-La Roche
Last refreshed: 27 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01566721.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT01566721: SafeHER

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Serious adverse events (345 terms)

Sponsor's own description

Publications & conference data

Related trials

Other trials of Herceptin

Other recruiting trials for Breast Neoplasms

Other Hoffmann-La Roche trials

Verify against primary sources